Treatment of early diffuse systemic sclerosis skin disease

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  Frech, Tracy M ^a   Shanmugam, Victoria K ^b   Shah, Ami A ^c   Assassi, Shervin ^d   Gordon, Jessica K ^e   Hant, Faye N ^f   Hinchcliff, Monique E ^g   Steen, Virginia ^b   Khanna, Dinesh ^h   Kayser, Cristiane ⁱ   Domsic, Robyn T ^j  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^j UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

Scleroderma; Skin disease; Systemic sclerosis; Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

COHORT ANALYSIS; DISEASE COURSE; DISEASE REGISTRY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EARLY INTERVENTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYSTEMIC SCLEROSIS; VASCULITIS; DIFFUSE SCLERODERMA; EARLY DIAGNOSIS; METABOLISM;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SCLERODERMA, DIFFUSE;

EID: 84883771144     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. LeROY EC, MEDSGER TA, Jr.: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
2. GRAF SW, HAKENDORF P, LESTER S et al.: South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15: 102-9.
3. HAMAGUCHI Y: Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010; 37: 42-53.
4. STEEN VD: The many faces of scleroderma. Rheum Dis Clin North Am 2008; 34: 1-15; v.
5. NIHTYANOVA SI, DENTON CP: Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6: 112-6.
6. QUILLINAN NP, DENTON CP: Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009; 21: 636-41.
7. CLEMENTS PJ, SEIBOLD JR, FURST DE et al.: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 2004; 33: 249-63.
8. POSTLETHWAITE AE, WONG WK, CLEMENTS P et al.: A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008; 58: 1810-22.
9. HOYLES RK, ELLIS RW, WELLSBURY J et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
10. WALKER KM, POPE J, participating members of the Scleroderma Clinical Trials C, Canadian Scleroderma Research G: Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42-55.
11. HERRICK AL, ENNIS H, BHUSHAN M, SILMAN AJ, BAILDAM EM: Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken) 2010; 62: 213-8.
12. KAYSER C, SEKIYAMA JY, PROSPERO LC, CAMARGO CZ, ANDRADE LE: Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S103-S108.
13. Della ROSSA A, CAZZATO M, d'ASCANIO A et al.: Alteration of microcirculation is a hallmark of very early SSc patients: a laser speckle contrast analysis. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S109-S114.
14. HARDING S, KHIMDAS S, BONNER A, BARON M, POPE J: Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). Clin Exp Rheumatol 2012; 30 (Suppl. 71): S38-43.
15. NESHER G, MOORE TL: The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum 1990; 33: 954-9.
16. JOHNSTON A, GUDJONSSON JE, SIGMUNDSDOTTIR H, LUDVIKSSON BR, VALDIMARSSON H: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-63.
17. GENESTIER L, PAILLOT R, FOURNEL S, FERRARO C, MIOSSEC P, REVILLARD JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-8.
18. GERARDS AH, de LATHOUDER S, de GROOT ER, DIJKMANS BA, AARDEN LA: Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 1189-96.
19. POPE JE, BELLAMY N, SEIBOLD JR et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.
20. van den HOOGEN FH, BOERBOOMS AM, SWAAK AJ, RASKER JJ, van LIER HJ, van de PUTTE LB: Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-72.
21. KOWAL-BIELECKA O, DISTLER O: Use of methotrexate in patients with scleroderma and mixed connective tissue disease. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S160-3.
22. JOHNSON SR, FELDMAN BM, POPE JE, TOMLINSON GA: Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 2009; 36: 323-9.
23. KOWAL-BIELECKA O, LANDEWé R, AVOUAC J et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
24. WALKER KM, POPE J: Scleroderma Clinical Trials C, Canadian Scleroderma Research G. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011; 38: 1326-8.
25. STRATTON RJ, WILSON H, BLACK CM: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40: 84-8.
26. NIHTYANOVA SI, BROUGH GM, BLACK CM, DENTON CP: Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 2007; 46: 442-5.
27. MENDOZA FA, NAGLE SJ, LEE JB, JIMENEZ SA: A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39: 1241-7.
28. DERK CT, GRACE E, SHENIN M, NAIK M, SCHULZ S, XIONG W: A prospective openlabel study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1595-9.
29. LE EN, WIGLEY FM, SHAH AA, BOIN F, HUMMERS LK: Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70: 1104-7.
30. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
31. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-34.
32. APRAS S, ERTENLI I, OZBALKAN Z et al.: Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48: 2256-61.
33. TEHLIRIAN CV, HUMMERS LK, WHITE B, BRODSKY RA, WIGLEY FM: High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 2008; 67: 775-81.
34. NADASHKEVICH O, DAVIS P, FRITZLER M, KOVALENKO W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-12.
35. PAONE C, CHIAROLANZA I, CUOMO G et al.: Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007; 25: 613-6.
36. BALEVA M, NIKOLOV K: The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol 2011; 2011: 829751.
37. BLANK M, LEVY Y, AMITAL H, SHOENFELD Y, PINES M, GENINA O: The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002; 46: 1689-90.
38. AMEMIYA K, SEMINO-MORA C, GRANGER RP, DALAKAS MC: Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94: 99-104.
39. LEVY Y, AMITAL H, LANGEVITZ P et al.: Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004; 50: 1005-7.
40. NACCI F, RIGHI A, CONFORTI ML et al.: Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007; 66: 977-9.
41. HERRICK AL, LUNT M, WHIDBY N et al.: Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010; 37: 116-24.